Welcome to our dedicated page for Esperion Therapeutics SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Esperion Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Esperion Therapeutics's regulatory disclosures and financial reporting.
Esperion Therapeutics (ESPR) – Form 4 insider filing: Chief Financial Officer Benjamin Halladay reported the sale of 7,229 common shares on 06/17/2025 at $1.152 per share, generating roughly $8,300 in proceeds. The company states the disposition was made solely to cover withholding taxes on recently-vested RSUs. Following the transaction, Halladay still directly holds 474,473 ESPR shares. No derivative transactions or additional dispositions were disclosed, and the filing indicates the sale was effected under a routine tax-settlement, not a 10b5-1 trading plan.